Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SYS6002 combined with JMT101 and SG001 in advanced head and neck squamous cell carcinoma
CTR20250884Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CRB-701, becotatug, PBI-1308 in head and neck squamous cell carcinoma (HNSCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Mar 2025; status: active.
02
Drugs
CRB-701becotatugPBI-1308
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20250884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250884.